Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs S 524101 (Primary)
  • Indications Allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Stallergenes Greer plc; Stallergenes SA

Most Recent Events

  • 04 May 2020 According to a Stallergenes Greer media release, it announces the submission of a marketing authorisation application for STAGR320, its sublingual house dust mite (HDM) immunotherapy (SLIT) tablet, via a European decentralized procedure.
  • 20 Nov 2018 According to a Stallergenes Greer plc media release, a full assessment of the data is ongoing, with detailed results expected to be presented at future scientific congresses, including the annual European Academy of Allergy and Clinical Immunology (EAACI) Congress.
  • 20 Nov 2018 Primary endpoint has been met. (Total Combined Score), according to a Stallergenes Greer plc media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top